Befejeződött4. fázis
A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy
A legfontosabb adatok
- Ki végzi
- Jazz Pharmaceuticals
- Hol
- Abington, Atlanta, Austin, Birmingham, Brandon, Chesterfield, Cincinnati, Cleveland, Columbia, Dublin, Gastonia, Houston, Huntersville, Irvine, Lakewood, Los Angeles, Miami, Newtown, Redwood City, Rincon, San Antonio, San Ramon, Santa Ana, Scottsdale, Scranton, Sterling Heights, Sugar Land és Winter Park (Egyesült Államok)Mind a 29 helyszín megnézéseMég 1 másik országban, 3 helyszínen
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 4. fázis
- Résztvevők
- 199 fő vett részt
- Kezdés
- 2023. júl. 27.
- Befejezés
- 2025. márc. 13.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- JZP258 (XYWAV)
- A regiszteradat frissítve
- 2026. augusztus 27.
Ki vehet részt
- Életkor
- 18 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 10 feltétel megnézéseKevesebb
Ki vehet részt
- Is 18 to 75 years of age (inclusive) at the time of signing the informed consent form (ICF)
- Has a primary diagnosis of IH meeting International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria or narcolepsy (Type 1 or Type 2) meeting ICSD-3 or Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria
- If not currently taking oxybate medication, has clinically significant symptoms of Excessive daytime sleepiness (EDS) with an ESS score > 10 at Screening Visit 1. If currently taking oxybate medication, has an ESS score > 10 at the Baseline Visit 2 polysomnography (after washout period). Note: Not applicable for participants entering the Narcolepsy >9-gram cohort (see additional criteria below for the Narcolepsy >9-gram cohort)
- If currently treated with anticataplectics and/or alerting agents, has been taking the same dosage for at least 1 month prior to Screening Visit 1 and has no current plans to adjust the dosage during the study period. Note: Alerting agents refer to either traditional stimulants (eg, amphetamines, methylphenidates) or wake-promoting agents (eg, modafinil, pitolisant, solriamfetol); Additional Inclusion Criteria for Participants in the Exploratory Narcolepsy >9-Gram Cohort
- Is on a current treatment regimen including XYWAV at a dosage of 9 grams
Ki nem vehet részt
- Has recently taken (ie, within 1 month prior to screening), is taking, or plans to take any of the following:; A substance or medication contraindicated with XYWAV use, ie. specifically alcohol and sedative hypnotics; A medication with a known drug-drug interaction with XYWAV; A medication that may have similar EEG effects to XYWAV; Medications known to have clinically significant CNS sedative effects; Other medications, natural health products, or substances from which the participant experiences clinically significant sedation; Additional Exclusion Criterion for Participants in the Exploratory Narcolepsy >9-Gram Cohort
- Has a history or presence of any unstable or clinically significant medical condition (chronic pain condition that may impact sleep), behavioral or psychiatric disorder (including active suicidal ideation or current or past [within 1 year] major depressive episode), or history or presence of another neurologic disorder or surgical history that might affect the participant's safety and/or interfere with the conduct of the study, in the opinion of the investigator
- Any past or current medical conditions or experience that, in the investigator's clinical judgment, would preclude further increases in the current oxybate medication dosage beyond 9 grams
- Shows evidence of a previous untreated or inadequately treated sleep disorder considered by the investigator to negatively impact the conduct of the study, including sleep-disordered breathing, parasomnias, circadian rhythm sleep disorders, or restless legs syndrome determined by a previous sleep-laboratory diagnosis or interview utilizing modules of the Diagnostic Interview for Sleep Patterns and Disorders
- Shows evidence of untreated or inadequately treated sleep-disordered breathing during Baseline Visit 2 polysomnography defined as an Apnea/Hypopnea Index (AHI) > 10, using the US Centers for Medicare and Medicaid Services rules (CMS.gov)
Helyszínek itt: Egyesült Államok
Még 1 másik országban, 3 helyszínen
- Abington Neurological Associates, LtdAbington, Egyesült Államok
- NeuroTrials Research IncAtlanta, Egyesült Államok
- FutureSearch Trials of NeurologyAustin, Egyesült Államok
- Sleep Disorders Center of AlabamaBirmingham, Egyesült Államok
- Meris Clinical Research, LLCBrandon, Egyesült Államok
- St. Lukes Hospital Medical CenterChesterfield, Egyesült Államok
- CTI Clinical Research CenterCincinnati, Egyesült Államok
- Intrepid ResearchCincinnati, Egyesült Államok
- Cleveland Clinic Main Campus - Clinical Research UnitCleveland, Egyesült Államok
- Bogan Sleep Consultants, LLCColumbia, Egyesült Államok
- Ohio Sleep Medicine and Neuroscience InstituteDublin, Egyesült Államok
- Clinical Research of GastoniaGastonia, Egyesült Államok
- Comprehensive Sleep Medicine AssociatesHouston, Egyesült Államok
- Stern Research Partners, LLCHuntersville, Egyesült Államok
- Amnova Clinical ResearchIrvine, Egyesült Államok
- Long Beach Research InstituteLakewood, Egyesült Államok
- Santa Monica Clinical TrialsLos Angeles, Egyesült Államok
- PharmaDev Clinical Research Institute, LLCMiami, Egyesült Államok
- Neurocare, Inc., dba Neurocare Center for ResearchNewtown, Egyesült Államok
- Stanford School of MedicineRedwood City, Egyesült Államok
- Centricity Research Rincon - DBA IACT Health Southeast Lung Associates ResearchRincon, Egyesült Államok
- Sleep Therapy Research CenterSan Antonio, Egyesült Államok
- TriValley Sleep CenterSan Ramon, Egyesült Államok
- SDS Clinical Trials, Inc.Santa Ana, Egyesült Államok
- Perseverance Research Center, LLCScottsdale, Egyesült Államok
- Geisinger ClinicScranton, Egyesült Államok
- Clinical Neurophysiology Services, P.C.Sterling Heights, Egyesült Államok
- Tricoastal Narcolepsy and Sleep Disorders CenterSugar Land, Egyesült Államok
- Florida Hospital for ChildrenWinter Park, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic hypersomnia (IH) or narcolepsy.
A vizsgálat csoportja
- JZP258A vizsgált kezelés
Participants will self-administer an oral dose of JZP258 (XYWAV) as per label and titrate to an optimal dosage for each participant.
Kezelés: JZP258 (XYWAV)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy
- Publikációk
- Symptom improvement with dosing above 9 g of low-sodium oxybate: effectiveness and safety in participants with narcolepsy in the DUET study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026
- Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study.Neurology and therapy, 2026
- Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study.CNS drugs, 2026
- A regiszteradat frissítve
- 2026. augusztus 27.